CD8A and melanoma: These results indicate that DCIL-15 is superior to rIL-15 in potentiating the antitumor efficacy of DNA-based cancer vaccines, leading to CD8+ T cell-dependent antitumor immunity against clinically-reflective BrafV600E/Pten-driven melanomas.